Details of the Drug Combinations

General Information of This Drug (ID: DM5ZTJL)

• Drug Name: Calmidazolium (DM5ZTJL)
• Synonyms: Calmidazolium ion; 95013-41-5; CHEBI:75400; R24571; MLS002172477; CHEMBL1208858; SMR001254103; SR-01000075486; Probes1_000251; Probes2_000292; Lopac0_000272; methoxy]ethyl]-1H-imidazolium; cid_644274; SCHEMBL8224791; CHEMBL1229168; BDBM76238; DTXSID30915173; BDBM50323389; HSCI1_000319; CCG-204367; NCGC00015233-02; NCGC00015233-03; NCGC00015233-04; NCGC00015233-08; NCGC00162113-01; NCGC00167775-01; 1-(Bis(4-chlorophenyl)methyl)-3-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)-1H-imidazolium; 1-[bis(4-chlorophenyl)methyl]-3-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazol-3-ium; 1-[bis(4-chlorophenyl)methyl]-3-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazol-3-ium; 1H-Imidazolium, 1-(bis(4-chlorophenyl)methyl)-3-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)-; SR-01000075486-7; SR-01000075486-8; BRD-A26199074-003-01-2; Q27145276; 3-[bis(4-chlorophenyl)methyl]-1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl); 1-[bis(4-chlorophenyl)methyl]-3-[2-(2,4-dichlorobenzyl)oxy-2-(2,4-dichlorophenyl)ethyl]imidazol-3-ium;chloride; 1-[Bis(4-chlorophenyl)methyl]-3-{2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl}-1H-imidazol-3-ium

Indication

Huntington disease; ICD 11: 8A01.10; Status: Investigative [1]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

3 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Calmidazolium + Lumefantrine	DC3GE9I	Lumefantrine	DD2 (Cell Line: DD2)	[2]
Calmidazolium + Piperaquine	DCNZPYC	Piperaquine	Hepatoblastoma (Cell Line: HB3)	[3]
NITD609 + Calmidazolium	DCREEWL	NITD609	Hepatoblastoma (Cell Line: HB3)	[3]

References

• [1] Calmidazolium Chloride and Its Complex with Serum Albumin Prevent Huntingtin Exon1 Aggregation. Mol Pharm. 2018 Aug 6;15(8):3356-3368.
• [2] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [3] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.